Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 113 (19), 4489-96

Prospective Outcome Data on 267 Unselected Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Confirms Superiority of Allogeneic Transplantation Over Chemotherapy in the Pre-Imatinib Era: Results From the International ALL Trial MRC UKALLXII/ECOG2993

Affiliations
Randomized Controlled Trial

Prospective Outcome Data on 267 Unselected Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Confirms Superiority of Allogeneic Transplantation Over Chemotherapy in the Pre-Imatinib Era: Results From the International ALL Trial MRC UKALLXII/ECOG2993

Adele K Fielding et al. Blood.

Abstract

Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR). The CR rate of 267 patients, median age 40, was 82%. Twenty-eight percent of patients proceeded to alloHSCT in first CR. Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT. At 5 years, overall survival (OS) was 44% after sib alloHSCT, 36% after MUD alloHSCT, and 19% after chemotherapy. After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT, only relapse-free survival remained significantly superior in the alloHSCT group (odds ratio 0.31, 95% confidence interval 0.16-0.61). An intention-to-treat analysis, using the availability or not of a matched sibling donor, showed 5-year OS to be nonsignificantly better at 34% with a donor versus 25% with no donor. This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223.

Figures

Figure 1
Figure 1
Flow chart showing all patients and treatments received.
Figure 2
Figure 2
Kaplan-Meier plot of overall survival by treatment received. Patients who failed to achieve remission on protocol and chemotherapy-treated patients who relapsed or died within 12 weeks of the start of treatment (the scheduled time for transplantation) are excluded from the analysis.
Figure 3
Figure 3
Kaplan-Meier plot of overall survival by availability of sibling donor among those in whom tissue typing was carried out and reported.

Similar articles

See all similar articles

Cited by 74 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback